[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axogen Inc (AXGN)

Axogen Inc (AXGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,670,359
  • Shares Outstanding, K 53,762
  • Annual Sales, $ 225,210 K
  • Annual Income, $ -15,700 K
  • EBIT $ -13 M
  • EBITDA $ -3 M
  • 60-Month Beta 1.11
  • Price/Sales 11.57
  • Price/Cash Flow N/A
  • Price/Book 10.17

Options Overview Details

View History
  • Implied Volatility 49.87% (+3.43%)
  • Historical Volatility 48.05%
  • IV Percentile 1%
  • IV Rank 3.92%
  • IV High 134.13% on 11/21/25
  • IV Low 46.43% on 08/12/26
  • Expected Move (DTE 8) 0.64 (1.33%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 160
  • Volume Avg (30-Day) 191
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,769
  • Open Int (30-Day) 3,522
  • Expected Range 47.27 to 48.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 2
  • High Estimate $-0.03
  • Low Estimate $-0.03
  • Prior Year $0.01
  • Growth Rate Est. (year over year) -400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.23 +25.11%
on 07/14/26
49.93 -4.20%
on 08/13/26
+8.34 (+21.12%)
since 07/13/26
3-Month
38.08 +25.62%
on 06/02/26
49.93 -4.20%
on 08/13/26
+7.54 (+18.71%)
since 05/13/26
52-Week
13.64 +250.66%
on 08/25/25
49.93 -4.20%
on 08/13/26
+33.07 (+224.05%)
since 08/13/25

Most Recent Stories

More News
AxoGen: Q2 Earnings Snapshot

AxoGen: Q2 Earnings Snapshot

AXGN : 47.88 (-3.60%)
Axogen, Inc. Reports Second Quarter 2026 Financial Results

ALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 47.88 (-3.60%)
AXGN's Streak of Earnings Victories May Have Set an Impossible Bar for Tomorrow

Barchart Research What to Expect from AXGN Earnings AXGN Generated July 28, 2026 Current Price $41.15 EPS Estimate $$-0.04 Consensus Rating Strong Buy Average Move 16.31% AXGN's Streak of Earnings Victories...

AXGN : 47.88 (-3.60%)
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experience Cory Anderson promoted to Executive Vice President and General Manager,...

AXGN : 47.88 (-3.60%)
STIM : 3.13 (-2.65%)
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 47.88 (-3.60%)
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected...

AXGN : 47.88 (-3.60%)
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...

AXGN : 47.88 (-3.60%)
TELA : 0.6914 (-4.00%)
ANIK : 21.40 (-2.88%)
MDXG : 4.21 (-1.64%)
ELUT : 0.8691 (+6.25%)
BVS : 13.98 (+0.50%)
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 47.88 (-3.60%)
AxoGen: Q1 Earnings Snapshot

AxoGen: Q1 Earnings Snapshot

AXGN : 47.88 (-3.60%)
Axogen, Inc. Reports First Quarter 2026 Financial Results

ALACHUA, Fla. and TAMPA, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 47.88 (-3.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch...

See More

Key Turning Points

3rd Resistance Point 51.93
2nd Resistance Point 50.92
1st Resistance Point 50.29
Last Price 47.88
1st Support Level 48.65
2nd Support Level 47.64
3rd Support Level 47.01

See More

52-Week High 49.93
Last Price 47.88
Fibonacci 61.8% 36.07
Fibonacci 50% 31.78
Fibonacci 38.2% 27.50
52-Week Low 13.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.